Pharmena mulls switch to WSE main market

Listed on the small-cap, alternative NewConnect market, biotechnology company Pharmena, plans to transfer its shares to the main WSE market by the end of this year, the company said in a market filing. In H1, the company had PLN 0.5 million net profit, compared with PLN 1.5 million loss last year. Revenues amounted to PLN 6.6 million,…

This content is for Silver 6 months, Gold 1 Year and Bronze 2 weeks members only.
Log In Buy Subscription
Pin It